News

Nuvectis licenses NXP100 and NXP200 from Haisco for ex-China rights to two late-stage compounds targeting rare disease and oncology...

MacroGenics receives $24.5M from Sanofi following FDA accelerated approval of TZIELD Stage 3 Type 1 Diabetes, with $305M in...

Eli Lilly's Centessa Acquisition approved by UK High Court for $7.8B, securing orexin receptor agonist programs targeting sleep and...

Insilico Medicine and SK Biopharmaceuticals partner on neuroimmune drug discovery with a deal valued above $2.5 billion, targeting neuroinflammatory...

Eli Lilly partners with BioArctic on blood-brain barrier drug delivery platform in $30M upfront deal with $770M in potential...

SK pharmteco partners with Orphan Therapeutics Accelerator to advance rare disease programs through manufacturing support and preferential pricing.

Chiesi presents five clinical abstracts on metreleptin at ENDO 2026, including Phase 3 trial data targeting label expansion in...

Kromatid names Matthew Hemstreet as permanent CEO to accelerate KROMASURE platform adoption amid FDA guidance on genome editing safety...

Constantiam and Cincinnati Children's partner to develop genotype-matched therapies for neuronopathic Gaucher disease, addressing a genetic disorder with over...

Memento Medicines raises $93M to develop MMT-205, a Tie2/VEGF bispecific antibody targeting retinal diseases nAMD and DME with clinical...